iPSC · Science & Clinical Progress
RESEARCH REVIEW / 2026-11-15

iPSC Science & Clinical Progress

SEE / UNDERSTAND / ASK

iPSC see how the idea works

Open any image at full size. Research pictures, original schematics and generated concepts are labelled separately; none is an Aurelia patient outcome.

Reprogramming brings somatic cells into a pluripotent state. Directed differentiation then aims at a specified cell identity. Disease models, drug screening and cell-product development have different goals; a laboratory result is not clinical permission.

iPSC: reprogramming and differentiation — Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.
Principle schematic

iPSC: reprogramming and differentiation

Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.

Original schematic · Aurelia · Scientific reference ↗
Human iPSC colony — Confocal image of an OCA1A research model. OCT4 is red, SSEA4 green and nuclei blue; this is not a treatment result.
Published research image

Human iPSC colony

Confocal image of an OCA1A research model. OCT4 is red, SSEA4 green and nuclei blue; this is not a treatment result.

NIH Image Gallery from Bethesda, Maryland, USA · Public domain
Image source ↗ · Original research / source ↗
Format and display notes

保留完整画幅和原有标注,仅等比例缩小并转WebP;原始文件同时保留。

Naïve human pluripotent cells — A human pluripotent colony on mouse feeder cells. The source does not specify ESC or iPSC origin; no such label is inferred.
Published research image

Naïve human pluripotent cells

A human pluripotent colony on mouse feeder cells. The source does not specify ESC or iPSC origin; no such label is inferred.

NergesW · CC BY-SA 4.0
Image source ↗ · Original research / source ↗
Format and display notes

原图为16位灰度TIFF;按65535→255线性缩放为8位显示并转WebP,保留完整画幅,不作局部增强或改动。原始TIFF同时保留。

Three directions for iPSC research — Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.
Principle schematic

Three directions for iPSC research

Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.

Original schematic · Aurelia · Scientific reference ↗
From hESCs to neurons — Panel A shows human embryonic stem cells; B shows derived neurons. These are hESCs, not iPSCs or patient before/after photographs.
Published research image

From hESCs to neurons

Panel A shows human embryonic stem cells; B shows derived neurons. These are hESCs, not iPSCs or patient before/after photographs.

Images: Nissim Benvenisty · CC BY 2.5
Image source ↗ · Original research / source ↗
Format and display notes

保留完整画幅和原有标注,仅等比例缩小并转WebP;原始文件同时保留。

Neural differentiation in culture — Human embryonic-stem-cell-derived neural progenitors after three weeks of maturation, with morphology and immune markers. Not iPSC or treatment-response images.
Published research image

Neural differentiation in culture

Human embryonic-stem-cell-derived neural progenitors after three weeks of maturation, with morphology and immune markers. Not iPSC or treatment-response images.

Nistor G, Siegenthaler MM, Poirier SN, Rossi S, Poole AJ, Charlton ME, et al. · CC BY 4.0
Image source ↗ · Original research / source ↗
Format and display notes

保留完整画幅和原有标注,仅等比例缩小并转WebP;原始文件同时保留。

What quality assessment looks at — Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.
Principle schematic

What quality assessment looks at

Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.

Original schematic · Aurelia · Scientific reference ↗
RESEARCH WATCH / 2026-11-16

Science & clinical progress

A curated weekly watch of primary research, trials and regulatory updates.

Clinical use, trial results and laboratory findings are different kinds of evidence. Source institutions are references, not declared Aurelia partners. Lack of published outcome numbers is shown explicitly.
2026-11-06 Laboratory research

A more practical iPSC organoid culture workflow

CiRA reports an improved hypothalamic–pituitary organoid protocol using feeder-cell composition and stable FGF2. Medium changes shift from daily to three times a week, with comparable differentiation efficiency.

7 → 3 medium changes / week

A laboratory workflow metric, not a patient outcome. Paper online 5 November; institutional news 6 November.

2026-11-06 Conditional approval · follow-up

RiHEART: third transplantation announced

The developer reports the third transplantation at Tokyo Women’s Medical University Hospital. The announcement records use after conditional, time-limited approval, not proof of a clinical success rate.

3 procedures announced; no quantitative outcome comparison

The product’s Japanese authorisation remains conditional and time-limited. This release does not provide long-term safety, control-group or before/after efficacy data.

2026-10-30 Clinical use · ongoing follow-up

Kyoto University Hospital begins Amchepry use

The hospital reports starting transplant surgery in October with the iPSC-derived dopaminergic precursor product. One woman in her fifties has been discharged and remains under follow-up.

1 publicly described postoperative case

Discharge is not a cure. No quantitative postoperative motor improvement was published in this notice; do not substitute the 2025 trial’s results for this person’s outcome.

Culture workflow · not a treatment outcome
Daily changes: 7 / week; Revised protocol: 3 / week01.753.55.257Daily changes7 / weekRevised protocol3 / week
View exact data
MeasurementValue
Daily changes7 / week
Revised protocol3 / week

CiRA organoid protocol, 6 November 2026. These numbers do not describe improvement in patients.

How iPSC works

Reprogramming gives mature cells a pluripotent state. Researchers then direct differentiation toward specific cells for replacement therapies, disease models or drug testing. The cell source alone does not determine safety or approval status.

2026 clinical milestone

On 6 March 2026 Japan granted conditional, time-limited marketing approvals to Amchepry for Parkinson’s disease and ReHeart for severe heart failure due to ischaemic cardiomyopathy. Their use remains indication-specific, with conditions and ongoing evidence requirements.

Organoids and drug discovery

A February 2026 CiRA study used iPSC-derived lung organoids to model impaired repair in fibrosis and screen candidate compounds. This illustrates a research tool for understanding disease, not an approved treatment for lung fibrosis.

Japan

The Act on the Safety of Regenerative Medicine governs relevant research and medical practice; the PMD Act governs commercial products. A provision-plan procedure is not product marketing approval or an efficacy guarantee.

United States

Check the exact FDA authorisation and indication, or the applicable investigational pathway. Trial registration alone is not marketing approval. Recognised cell therapies do not authorise unrelated wellness claims.

China

State Council Order 818 took effect on 1 May 2026. Distinguish research filing, clinical-translation approval and drug marketing authorisation. Related research fees must not be charged to participants; approved clinical application follows the applicable charging rules.